A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processes

Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen

Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763 · see citing works

The STATs of cancer — new molecular targets come of age

Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · see citing works

STATs in oncogenesis

Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743 · see citing works

Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells

Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638 · see citing works

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207 · see citing works

The role of STATs in transcriptional control and their impact on cellular function

Bromberg, J., & Darnell, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203476 · Cited by 1,201 · see citing works

Transcription factors as targets for cancer therapy

Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194 · see citing works

Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

Buettner, R., Mora, L. B., & Jove, R. (2002) · PubMed · Cited by 1,021 · see citing works

Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein

Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931 · see citing works

Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions

Shuai, K., Horvath, C. M., Huang, L. H. T., Qureshi, S. A., Cowburn, D., & Darnell, J. E. (1994) · Cell · doi:10.1016/0092-8674(94)90357-3 · Cited by 807 · see citing works

Three-dimensional structure of the Stat3β homodimer bound to DNA

Becker, S., Groner, B., & Müller, C. W. (1998) · Nature · doi:10.1038/28101 · Cited by 792 · see citing works

Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells

Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro‐Cacho, C., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S. J., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204349 · Cited by 747 · see citing works

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B. M., Lawrence, H. R., Yip, M. L. R., Jove, R., McLaughlin, M. M., Lawrence, N. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609757104 · Cited by 734 · see citing works

Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation

Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., & Jove, R. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2545 · Cited by 651 · see citing works

STAT proteins: novel molecular targets for cancer drug discovery

Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1204086 · Cited by 643 · see citing works

Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.

Blaskovich, M. A., Sun, J., Cantor, A. B., Turkson, J., Jove, R., & Sebti, S. M. (2003) · PubMed · Cited by 567 · see citing works

Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells

Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563 · see citing works

Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis

Wei, D., Le, X., Zheng, L., Wang, L., Frey, J. A., Gao, A. C., Peng, Z., Huang, S., Xiong, H. Q., Abbruzzese, J. L., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206122 · Cited by 558 · see citing works

Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis

Xie, T., Wei, D., Liu, M., Gao, A. C., Ali‐Osman, F., Sawaya, R. A., & Huang, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207383 · Cited by 550 · see citing works

Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.

Mora, L. B., Buettner, R., Seigne, J. D., Diaz, J. I., Ahmad, N., Garcia, R., Bowman, T. L., Falcone, R., Fairclough, R., Cantor, A. B., et al. (2002) · PubMed · Cited by 532 · see citing works

A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells

Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504 · see citing works

STAT3 as a target for inducing apoptosis in solid and hematological tumors

Siddiquee, K., & Turkson, J. (2008) · Cell Research · doi:10.1038/cr.2008.18 · Cited by 488 · see citing works

Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation

Turkson, J., Ryan, D., Kim, J. S., Zhang, Y., Chen, Z. J., Haura, E. B., Laudano, A., Sebti, S. M., Hamilton, A. D., & Jove, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107527200 · Cited by 448 · see citing works

Targeting STAT3 in cancer: how successful are we?

Yue, P.-B., & Turkson, J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802565791 · Cited by 425 · see citing works

Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity.

Seidel, H. M., Milocco, L. H., Lamb, P., Darnell, J. E., Stein, R. B., & Rosen, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.3041 · Cited by 415 · see citing works

Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells

Real, P. J., Sierra, A., de Juan, A., Segovia, J. C., Lopez-Vega, J. M., & Fernandez-Luna, J. L. (2002) · Oncogene · doi:10.1038/sj.onc.1206004 · Cited by 321 · see citing works

Immortal Human Pancreatic Duct Epithelial Cell Lines with Near Normal Genotype and Phenotype

Ouyang, H. W., Mou, L.-J., Luk, C. K., Liu, N., Karásková, J., Squire, J. A., & Tsao, M. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64800-6 · Cited by 316 · see citing works

Validating Stat3 in cancer therapy

Darnell, J. E. (2005) · Nature Medicine · doi:10.1038/nm0605-595 · Cited by 307 · see citing works

STAT proteins as novel targets for cancer drug discovery

Turkson, J. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.5.409 · Cited by 295 · see citing works

Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity

Sun, J., Blaskovich, M. A., Jove, R., Livingston, S. K., Coppola, D., & Sebti, S. M. (2005) · Oncogene · doi:10.1038/sj.onc.1208470 · Cited by 263 · see citing works

Requirement for Ras/Rac1-Mediated p38 and c-Jun N-Terminal Kinase Signaling in Stat3 Transcriptional Activity Induced by the Src Oncoprotein

Turkson, J., Bowman, T. L., Adnane, J., Zhang, Y., Djeu, J. Y., Sekharam, M., Frank, D. A., Holzman, L. B., Wu, J., Sebti, S. M., et al. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7519 · Cited by 256 · see citing works

Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity

Turkson, J., Kim, J. S., Zhang, S., Yuan, J., Huang, M., Glenn, M. P., Haura, E. B., Sebti, S. M., Hamilton, A. D., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.261.3.3 · Cited by 255 · see citing works

The STAT3 isoforms α and β have unique and specific functions

Maritano, D., Sugrue, M. L., Tininini, S., Dewilde, S., Strobl, B., Fu, X., Murray-Tait, V., Chiarle, R., & Poli, V. (2004) · Nature Immunology · doi:10.1038/ni1052 · Cited by 234 · see citing works

Role of Stat3 in suppressing anti-tumor immunity

Kortylewski, M., & Yu, H. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.03.010 · Cited by 196 · see citing works

An Oxazole-Based Small-Molecule Stat3 Inhibitor Modulates Stat3 Stability and Processing and Induces Antitumor Cell Effects

Siddiquee, K., Gunning, P. T., Glenn, M. P., Katt, W. P., Zhang, S., Schrock, C. E., Sebti, S. M., Jove, R., Hamilton, A. D., & Turkson, J. (2007) · ACS Chemical Biology · doi:10.1021/cb7001973 · Cited by 188 · see citing works

Overexpressed pp60c-src can induce focus formation without complete transformation of NIH 3T3 cells.

Johnson, P. J., Coussens, P. M., Danko, A. V., & Shalloway, D. I. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.5.1073 · Cited by 168 · see citing works

Activation of Stat3 in v-Src-transformed Fibroblasts Requires Cooperation of Jak1 Kinase Activity

Zhang, Y., Turkson, J., Carter‐Su, C., Smithgall, T. E., Levitzki, A., Kraker, A. J., Krolewski, J. J., Medveczky, P. G., & Jove, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002383200 · Cited by 164 · see citing works

A Novel Platinum Compound Inhibits Constitutive Stat3 Signaling and Induces Cell Cycle Arrest and Apoptosis of Malignant Cells

Turkson, J., Zhang, S., Mora, L. B., Burns, A. C., Sebti, S. M., & Jove, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502694200 · Cited by 151 · see citing works

Paradigm shifts in the cell biology of STAT signaling

Sehgal, P. B. (2008) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2008.07.003 · Cited by 130 · see citing works

Identification of a High-Affinity Phosphopeptide Inhibitor of Stat3

Ren, Z., Cabell, L. A., Schaefer, T. S., & McMurray, J. S. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)01050-8 · Cited by 128 · see citing works

Investigation of the Binding Determinants of Phosphopeptides Targeted to the Src Homology 2 Domain of the Signal Transducer and Activator of Transcription 3. Development of a High-Affinity Peptide Inhibitor

Coleman, Ren, Z., Mandal, P. K., Cameron, A. G., Dyer, G. A., Muranjan, S., Campbell, M. L., Chen, X., & McMurray, J. S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050513m · Cited by 127 · see citing works

Inhibition of STAT3Tyr705 Phosphorylation by Smad4 Suppresses Transforming Growth Factor β–Mediated Invasion and Metastasis in Pancreatic Cancer Cells

Zhao, S., Venkatasubbarao, K., Lazor, J. W., Sperry, J. C., Jin, C., Cao, L., & Freeman, J. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5123 · Cited by 115 · see citing works

Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development

Bromberg, J. (2000) · Breast Cancer Research · doi:10.1186/bcr38 · Cited by 114 · see citing works

A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3

Schust, J., & Berg, T. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.03.024 · Cited by 109 · see citing works

Molecular Approaches towards the Inhibition of the Signal Transducer and Activator of Transcription 3 (Stat3) Protein

Fletcher, S., Turkson, J., & Gunning, P. T. (2008) · ChemMedChem · doi:10.1002/cmdc.200800123 · Cited by 104 · see citing works

Stat3 as a Potential Target for Cancer Immunotherapy

Kortylewski, M., & Yu, H. (2007) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211327.76266.65 · Cited by 93 · see citing works

LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model

Fuh, B., Sobo, M., Cen, L., Josiah, D. T., Hutzen, B. J., Cisek, K. K., Bhasin, D. K., Regan, N., Lin, L., Chan, C., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604793 · Cited by 93 · see citing works

Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro

Huang, C., Cao, J., Huang, K., Zhang, F., Jiang, T., Zhu, L., & Qiu, Z. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00340.x · Cited by 91 · see citing works

Disruption of Transcriptionally Active Stat3 Dimers with Non‐phosphorylated, Salicylic Acid‐Based Small Molecules: Potent in vitro and Tumor Cell Activities

Fletcher, S., Singh, J., Zhang, X., Yue, P., Page, B. D. G., Sharmeen, S., Shahani, V. M., Zhao, W. M., Schimmer, A. D., Turkson, J., et al. (2009) · ChemBioChem · doi:10.1002/cbic.200900172 · Cited by 87 · see citing works

Design, synthesis, and studies of small molecule STAT3 inhibitors

Bhasin, D. K., Cisek, K. K., Pandharkar, T., Regan, N., Li, C., Pandit, B., Lin, J., & Li, P. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.10.031 · Cited by 87 · see citing works

Enhanced Expression of the Type II Transforming Growth Factor-β Receptor Is Associated with Decreased Survival in Human Pancreatic Cancer

Wagner, M., Kleeff, J. H., Frieß, H., Büchler, M. W., & Korc, M. (1999) · Pancreas · doi:10.1097/00006676-199911000-00008 · Cited by 83 · see citing works

Prolactin and interleukin-2 receptors in T lymphocytes signal through a MGF-STAT5-like transcription factor

Gouilleux, F., Moritz, D. R., Humar, M., Moriggl, R., Berchtold, S., & Groner, B. (1995) · Endocrinology · doi:10.1210/endo.136.12.7588326 · Cited by 68 · see citing works

Targeting Protein–Protein Interactions: Suppression of Stat3 Dimerization with Rationally Designed Small‐Molecule, Nonpeptidic SH2 Domain Binders

Gunning, P. T., Glenn, M. P., Siddiquee, K., Katt, W. P., Masson, E., Sebti, S. M., Turkson, J., & Hamilton, A. D. (2008) · ChemBioChem · doi:10.1002/cbic.200800291 · Cited by 50 · see citing works

Preassociation of nonactivated STAT3 molecules demonstrated in living cells using bioluminescence resonance energy transfer: a new model of STAT activation?

Schröder, M., Kroeger, K. M., Volk, H., Eidne, K. A., & Grütz, G. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.1003496 · Cited by 41 · see citing works

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110 · see citing works

The JAK/STAT signaling pathway: from bench to clinic

Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633 · see citing works

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

O’Shea, J. J., & Plenge, R. M. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.014 · Cited by 1,146 · see citing works

Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies

Sansone, P., & Bromberg, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8907 · Cited by 511 · see citing works

Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer

Ouyang, S., Li, H., Lou, L., Huang, Q., Zhang, Z., Mo, J., Li, M., Lu, J., Zhu, K., Chu, Y., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102317 · Cited by 507 · see citing works

Therapeutic modulators of STAT signalling for human diseases

Miklóssy, G., Hilliard, T. S., & Turkson, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4088 · Cited by 410 · see citing works

Strategies and Approaches of Targeting STAT3 for Cancer Treatment

Furtek, S. L., Backos, D. S., Matheson, C. J., & Reigan, P. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00945 · Cited by 348 · see citing works

Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts

Zhang, X., Yue, P., Page, B. D. G., Li, T., Zhao, W. M., Namanja, A. T., Paladino, D., Zhao, J., Chen, Y., Gunning, P. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121606109 · Cited by 347 · see citing works

Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism

Zhao, C., Li, H., Lin, H.-J. L., Yang, S., Lin, J., & Liang, G. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.001 · Cited by 235 · see citing works

Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway

Ren, X., Duan, L., He, Q., Zhang, Z., Zhou, Y., Wu, D., Pan, J., Pei, D., & Ding, K. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100146z · Cited by 232 · see citing works

Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation

Dong, J., Cheng, X.-D., Zhang, W.-D., & Qin, J.-J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00629 · Cited by 232 · see citing works

STAT3 in the Systemic Inflammation of Cancer Cachexia

Zimmers, T., Fishel, M., & Bonetto, A. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.02.009 · Cited by 216 · see citing works

Tumor microenvironment in ovarian cancer: function and therapeutic strategy

Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218 · see citing works

Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy

Bose, S., Banerjee, S., Mondal, A., Chakraborty, U., Pumarol, J., Croley, C. R., & Bishayee, A. (2020) · Cells · doi:10.3390/cells9061451 · Cited by 218 · see citing works

Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein

Debnath, B., Xu, S., & Neamati, N. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300207s · Cited by 205 · see citing works

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers

Wang, X., Crowe, P. J., Goldstein, D., & Yang, J. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1568 · Cited by 202 · see citing works

STAT inhibitors for cancer therapy

Furqan, M., Akinleye, A., Mukhi, N., Mittal, V., Chen, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-90 · Cited by 191 · see citing works

Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation

Sun, C. C., Vaja, V., Babitt, J. L., & Lin, H. Y.-F. (2011) · American Journal of Hematology · doi:10.1002/ajh.23110 · Cited by 181 · see citing works

A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation

Zhang, X., Sun, Y., Pireddu, R., Yang, H., Urlam, M. K., Lawrence, H. R., Guida, W. C., Lawrence, N. J., & Sebti, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3175 · Cited by 148 · see citing works

Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?

Beebe, J., Liu, J., & Zhang, J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.006 · Cited by 142 · see citing works

Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells

Yue, P., Zhang, X., Paladino, D., Sengupta, B., Ahmad, S., Holloway, R. W., Ingersoll, S. B., & Turkson, J. (2011) · Oncogene · doi:10.1038/onc.2011.409 · Cited by 135 · see citing works

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia

Eiring, A. M., Page, B. D. G., Kraft, I. L., Mason, C. C., Vellore, N. A., Resetca, D., Zabriskie, M. S., Zhang, T. Y., Khorashad, J. S., Engar, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.245 · Cited by 132 · see citing works

Hepcidin antagonists for potential treatments of disorders with hepcidin excess

Poli, M., Asperti, M., Ruzzenenti, P., Regoni, M., & Arosio, P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00086 · Cited by 124 · see citing works

Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening

Liu, L., Leung, K., Chan, D. S.-H., Wang, Y.-T., Ma, D., & Leung, C.-H. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.250 · Cited by 123 · see citing works

Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma

Bharadwaj, U., Eckols, T. K., Xu, X.-J., Kasembeli, M., Chen, Y.-Y., Adachi, M., Song, Y.-C., Mo, Q., Lai, S., & Tweardy, D. (2016) · OncoTarget · doi:10.18632/oncotarget.8368 · Cited by 100 · see citing works

Progress towards the development of SH2 domain inhibitors

Kraskouskaya, D., Duodu, E., Arpin, C. C., & Gunning, P. T. (2013) · Chemical Society Reviews · doi:10.1039/c3cs35449k · Cited by 114 · see citing works

Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3

Zhang, T., Li, J., Yin, F., Lin, B., Wang, Z., Xu, J., Wang, H., Zuo, D., Wang, G., Hua, Y., et al. (2017) · Oncogene · doi:10.1038/onc.2017.270 · Cited by 132 · see citing works

The JAK/STAT signaling cascade in gastric carcinoma (Review)

Khanna, P., Chua, P. J., Bay, B., & Baeg, G. H. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3160 · Cited by 106 · see citing works

XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

Cheng, Y., Holloway, M. P., Nguyen, K., McCauley, D., Landesman, Y., Kauffman, M. G., Shacham, S., & Altura, R. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0416 · Cited by 105 · see citing works

Targeting STAT3 in cancer and autoimmune diseases

Gharibi, T., Babaloo, Z., Hosseini, A., Abdollahpour‐Alitappeh, M., Hashemi, V., Marofi, F., Nejati‐Koshki, K., & Baradaran, B. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173107 · Cited by 104 · see citing works

Signal transducer and activator of transcription 3 inhibitors: a patent review

Page, B. D. G., Ball, D. P., & Gunning, P. T. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.539205 · Cited by 103 · see citing works

Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity

Page, B. D. G., Khoury, H., Laister, R. C., Fletcher, S., Vellozo, M., Manzoli, A., Yue, P., Turkson, J., Minden, M. D., & Gunning, P. T. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200720n · Cited by 99 · see citing works

Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?

Huang, Q., Zhong, Y., Dong, H., Zheng, Q., Shi, S., Zhu, K., Qu, X., Hu, W., Zhang, X., & Wang, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111922 · Cited by 93 · see citing works

Overview of the STAT‑3 signaling pathway in cancer and the development of specific inhibitors (Review)

Gu, Y., Mohammad, I., & Liu, Z. (2020) · Oncology Letters · doi:10.3892/ol.2020.11394 · Cited by 95 · see citing works

Anticancer activity and SAR studies of substituted 1,4-naphthoquinones

Bhasin, D. K., Chettiar, S. N., Etter, J. P., Mok, M., & Li, P. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.05.017 · Cited by 86 · see citing works

Structurally Modified Curcumin Analogs Inhibit STAT3 Phosphorylation and Promote Apoptosis of Human Renal Cell Carcinoma and Melanoma Cell Lines

Bill, M. A., Nicholas, C., Mace, T. A., Etter, J. P., Li, C., Schwartz, E. B., Fuchs, J. R., Young, G. S., Lin, L., Lin, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040724 · Cited by 84 · see citing works

STAT signaling in the pathogenesis and treatment of myeloid malignancies

Bar-Natan, M., Nelson, E., Xiang, M., & Frank, D. (2012) · JAK-STAT · doi:10.4161/jkst.20006 · Cited by 87 · see citing works

STAT3: A Potential Drug Target for Tumor and Inflammation

Hu, Y. S., Han, X., & Liu, X. H. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190620145052 · Cited by 81 · see citing works

Signal Transducer and Activator of Transcription 3 (STAT3): A Promising Target for Anticancer Therapy

Masciocchi, D., Gelain, A., Villa, S., Meneghetti, F., & Barlocco, D. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.22 · Cited by 78 · see citing works

A Cell-permeable Stat3 SH2 Domain Mimetic Inhibits Stat3 Activation and Induces Antitumor Cell Effects in Vitro

Zhao, W. M., Jaganathan, S., & Turkson, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.154088 · Cited by 73 · see citing works

Hydroxamic Acid and Benzoic Acid–Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo

Yue, P., Lopez‐Tapia, F., Paladino, D., Li, Y., Chen, C., Namanja, A. T., Hilliard, T. S., Chen, Y., Tius, M. A., & Turkson, J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3558 · Cited by 72 · see citing works

STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment

Lavecchia, A., Giovanni, C. D., & Novellino, E. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795843218 · Cited by 67 · see citing works

Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance

Dzobo, K., & Dandara, C. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0023 · Cited by 65 · see citing works

Interleukin-6 serves as a critical factor in various cancer progression and therapy

Mohamed, A. H., Ahmed, A. T., Abdulmonem, W. A., Bokov, D. O., Shafie, A., Al‐Hetty, H. R. A. K., Hsu, C., Alissa, M., Nazir, S., Jamali, M. C., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02422-5 · Cited by 68 · see citing works

Methylation of SLFN11 is a Marker of Poor Prognosis and Cisplatin Resistance in Colorectal Cancer

He, T., Zhang, M., Zheng, R., Zheng, S., Linghu, E., Herman, J. G., & Guo, M. (2017) · Epigenomics · doi:10.2217/epi-2017-0019 · Cited by 64 · see citing works

Negative regulators of STAT3 signaling pathway in cancers

Wu, M., Song, D., Li, H. Z., Yang, Y., Ma, X., Deng, S., Ren, C., & Shu, X. H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s206175 · Cited by 64 · see citing works

A Novel Small Molecular STAT3 Inhibitor, LY5, Inhibits Cell Viability, Cell Migration, and Angiogenesis in Medulloblastoma Cells

Xiao, H., Bid, H. K., Jou, D., Wu, X., Yu, W., Li, C., Houghton, P. J., & Lin, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.616748 · Cited by 63 · see citing works

Targeting Sh2 Domains in Breast Cancer

Morlacchi, P., Robertson, F. M., Klostergaard, J., & McMurray, J. S. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.120 · Cited by 63 · see citing works

STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion

Zhou, C., Jiao, Y., Wang, R., Ren, S.-G., Wawrowsky, K., & Melmed, S. K. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78173 · Cited by 61 · see citing works

A STAT inhibitor patent review: progress since 2011

Lai, P., Rosa, D. A., Ali, A. M., Gómez‐Biagi, R. F., Ball, D. P., Shouksmith, A. E., & Gunning, P. T. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1086749 · Cited by 59 · see citing works

Bioactive sesquiterpene lactones and other compounds isolated from Vernonia cinerea

Youn, U. J., Miklóssy, G., Chai, X., Wongwiwatthananukit, S., Toyama, O., Songsak, T., Turkson, J., & Chang, L. C. (2013) · Fitoterapia · doi:10.1016/j.fitote.2013.12.013 · Cited by 59 · see citing works

Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain

Page, B. D. G., Fletcher, S., Yue, P., Li, Z., Zhang, X., Sharmeen, S., Datti, A., Wrana, J. L., Trudel, S., Schimmer, A. D., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.056 · Cited by 58 · see citing works

An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery

Mitra, R. N., Doshi, M., Zhang, X., Tyus, J. C., Bengtsson, N. E., Fletcher, S., Page, B. D. G., Turkson, J., Gesquiere, A. J., Gunning, P. T., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.068 · Cited by 57 · see citing works

STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy

Yang, P.-L., Liu, L.-X., Li, E., & Xu, L. (2020) · Cancers · doi:10.3390/cancers12092459 · Cited by 54 · see citing works

YM155 Induces EGFR Suppression in Pancreatic Cancer Cells

Na, Y.-S., Yang, S., Kim, S.-M., Jung, K.-A., Moon, J.-H., Shin, J.-S., Yoon, D. H., Hong, Y. S., Ryu, M., Lee, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038625 · Cited by 54 · see citing works

STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy

Camporeale, A., Marino, F., Papageorgiou, A., Carai, P., Fornero, S., Fletcher, S., Page, B., Gunning, P., Forni, M., Chiarle, R., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201876 · Cited by 48 · see citing works

Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3

Huang, R.-Z., Jing, X.-T., Huang, X., Pan, Y.-M., Fang, Y., Liang, G.-B., Liao, Z., Wang, H., Chen, Z., & Zhang, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01386 · Cited by 48 · see citing works

Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking

Yu, W., Li, C., Zhang, W., Xia, Y., Li, S., Lin, J., Yu, K., Liu, M., Yang, L. F., Luo, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01489 · Cited by 48 · see citing works

Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization

Resetca, D., Haftchenary, S., Gunning, P. T., & Wilson, D. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.595454 · Cited by 47 · see citing works

Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain

Hua, Y., Xing, Y., Shen, Y., Wang, J., Azeem, W., Yang, S., Gade, A., Lellahi, S. M., Oyan, A. M., Ke, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.836724 · Cited by 44 · see citing works

Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro

Gürbüz, V., Konaç, E., Varol, N., Yılmaz, A., Gürocak, S., Menevşe, S., & Sözen, S. (2014) · Oncology Letters · doi:10.3892/ol.2014.1795 · Cited by 44 · see citing works

Withaferin A Inhibits STAT3 and Induces Tumor Cell Death in Neuroblastoma and Multiple Myeloma

Yco, L., Mócz, G., Opoku‐Ansah, J., & Bachmann, A. S. (2014) · Biochemistry Insights · doi:10.4137/bci.s18863 · Cited by 43 · see citing works

Discovery of Novel Azetidine Amides as Potent Small-Molecule STAT3 Inhibitors

Brotherton‐Pleiss, C., Yue, P., Zhu, Y., Nakamura, K., Chen, W., Fu, W., Kubota, C. S., Chen, J., Alonso-Valenteen, F., Mikhael, S., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01705 · Cited by 43 · see citing works

Identification of new shikonin derivatives as STAT3 inhibitors

Qiu, H., Fu, J., Yang, M., Han, H., Wang, P., Zhang, Y., Lin, H., Tang, C., Qi, J., Yang, R., et al. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.10.009 · Cited by 40 · see citing works

Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents against Multiple Myeloma

Page, B. D. G., Croucher, D. C., Li, Z., Haftchenary, S., Jimenez-Zepeda, V. H., Atkinson, J. M., Spagnuolo, P. A., Wong, Y. L., Colaguori, R., Lewis, A. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017255 · Cited by 38 · see citing works

Identification of STAT1 and STAT3 Specific Inhibitors Using Comparative Virtual Screening and Docking Validation

Szeląg, M., Czerwoniec, A., Wesoły, J., & Bluyssen, H. A. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116688 · Cited by 38 · see citing works

Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma

Huang, Y.-H., Vakili, M. R., Molavi, O., Morrissey, Y. C., Wu, C., de Paiva, I. M., Soleimani, A. H., Sanaee, F., Lavasanifar, A., & Lai, R. L. (2019) · Cancers · doi:10.3390/cancers11020248 · Cited by 38 · see citing works

Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein

Shahani, V. M., Yue, P., Fletcher, S., Sharmeen, S., Sukhai, M. A., Luu, D. P., Zhang, X., Sun, H., Zhao, W. M., Schimmer, A. D., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.12.010 · Cited by 37 · see citing works

STAT3‐Interacting Proteins as Modulators of Transcription Factor Function: Implications to Targeted Cancer Therapy

Yeh, J., & Frank, D. A. (2015) · ChemMedChem · doi:10.1002/cmdc.201500482 · Cited by 37 · see citing works

Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors

Pallandre, J., Borg, C., Rognan, D., Boibessot, T., Luzet, V., Yesylevskyy, S. O., Ramseyer, C., & Pudlo, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.054 · Cited by 37 · see citing works

Protein Kinase C Zeta Regulates Human Pancreatic Cancer Cell Transformed Growth and Invasion through a STAT3-Dependent Mechanism

Saravia-Butler, A., Scotti, M. L., Li, S., Smith, K. E., Fields, A. P., & Murray, N. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072061 · Cited by 36 · see citing works

A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.

Auzenne, E. J., Klostergaard, J., Mandal, P. K., Liao, W. S. ‐., Lü, Z., Gao, F., Bast, R. C., Robertson, F. M., & McMurray, J. S. (2012) · PubMed · Cited by 36 · see citing works

Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain

Qiu, H., Zhu, X., Luo, Y., Lin, H., Tang, C., Qi, J., Pang, Y.-J., Yang, R., Lu, G., Wang, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02671-7 · Cited by 35 · see citing works

STAT3 inhibitor NSC74859 radiosensitizes esophageal cancer via the downregulation of HIF-1α

Zhang, C., Yang, X., Zhang, Q., Guo, Q., He, J., Qin, Q., Zhu, H., Liu, J., Zhan, L., Lü, J., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2207-3 · Cited by 35 · see citing works

2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors

Lamie, P. F., & Philoppes, J. N. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1740922 · Cited by 34 · see citing works

LL1, a novel and highly selective STAT3 inhibitor, displays anti‐colorectal cancer activities in vitro and in vivo

Liu, Z., Wang, H., Guan, L., Lai, C., Yu, W., & Lai, M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14863 · Cited by 32 · see citing works

A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction

Park, S. K., Byun, W. S., Lee, S., Han, Y. T., Jeong, Y., Jang, K., Chung, S., Lee, J., Suh, Y., & Lee, S. K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114053 · Cited by 32 · see citing works

MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling

Park, J., Kim, S., Joh, J. J., Remick, S. C., Miller, D. M., Yan, J., Kanaan, Z., Chao, J.-H., Krem, M. M., Basu, S. K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9759 · Cited by 31 · see citing works

Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma

Miklóssy, G., Youn, U. J., Yue, P., Zhang, M., Chen, C.-H., Hilliard, T. S., Paladino, D., Li, Y., Choi, J. C.-B., Sarkaria, J. N., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00686 · Cited by 29 · see citing works

Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy

Feng, K.-R., Wang, F., Shi, X., Tan, Y., Zhao, J., Zhang, J., Li, Q., Lin, G., Gao, D., & Tian, P. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112428 · Cited by 29 · see citing works

Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours

Zhang, X., Blaskovich, M. A., Forinash, K. D., & Sebti, S. M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.349 · Cited by 29 · see citing works

A Resveratrol Analogue Promotes ERKMAPK–Dependent Stat3 Serine and Tyrosine Phosphorylation Alterations and Antitumor Effects In Vitro against Human Tumor Cells

Chelsky, Z. L., Yue, P., Kondratyuk, T. P., Paladino, D., Pezzuto, J. M., Cushman, M., & Turkson, J. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.099093 · Cited by 28 · see citing works

Tagging of Genomic STAT3 and STAT1 with Fluorescent Proteins and Insertion of a Luciferase Reporter in the Cyclin D1 Gene Provides a Modified A549 Cell Line to Screen for Selective STAT3 Inhibitors

Samsonov, A., Zenser, N., Zhang, F., Zhang, H., Fetter, J. R., & Malkov, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068391 · Cited by 26 · see citing works

Discovery of a small-molecule inhibitor of STAT3 by ligand-based pharmacophore screening

Leung, K., Liu, L., Lin, S., Lu, L., Zhong, H., Susanti, D., Rao, W., Wang, M., Che, W. I., Chan, D. S., et al. (2014) · Methods · doi:10.1016/j.ymeth.2014.07.010 · Cited by 26 · see citing works

Iridoid Glycosides from Barleria lupulina

Kim, K. H., Park, Y. J., Chung, K. H., Yip, M. L. R., Clardy, J., Senger, D. R., & Cao, S. (2015) · Journal of Natural Products · doi:10.1021/np500791a · Cited by 26 · see citing works

Critical analysis of the potential for targeting STAT3 in human malignancy

Grandis, J., & Peyser (2013) · OncoTargets and Therapy · doi:10.2147/ott.s47903 · Cited by 24 · see citing works

Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo

Yue, P., Zhu, Y., Brotherton‐Pleiss, C., Fu, W., Verma, N., Chen, J., Nakamura, K., Chen, W., Chen, Y., Alonso-Valenteen, F., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215613 · Cited by 24 · see citing works

Extolling the benefits of molecular therapeutic lipidation

Avadisian, M., & Gunning, P. T. (2013) · Molecular BioSystems · doi:10.1039/c3mb70147f · Cited by 24 · see citing works

Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors

Furtek, S. L., Matheson, C. J., Backos, D. S., & Reigan, P. (2016) · Oncotarget · doi:10.18632/oncotarget.12868 · Cited by 24 · see citing works

Genetic Interactions of STAT3 and Anticancer Drug Development

Fang, B. (2014) · Cancers · doi:10.3390/cancers6010494 · Cited by 24 · see citing works

The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain

McMurray, J. S., Mandal, P. K., Liao, W. S. ‐., Klostergaard, J., & Robertson, F. M. (2012) · JAK-STAT · doi:10.4161/jkst.22682 · Cited by 23 · see citing works

STAT3 Inhibitors in Cancer: A Comprehensive Update

Bharadwaj, U., Kasembeli, M. M., & Tweardy, D. J. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-42949-6_5 · Cited by 23 · see citing works

Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3

Ma, S., Zhu, L., Fan, X., Luo, T., Liu, D., Liang, Z., Hu, X., Shi, T., Tan, W., & Wang, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113027 · Cited by 23 · see citing works

Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling

Chen, L., Feng, D., Qian, Y., Cheng, X., Song, H., Qian, Y., Zhang, X., Wu, Y., Lv, H., Liu, Q., et al. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153537 · Cited by 23 · see citing works

Research progress of STAT3-based dual inhibitors for cancer therapy

Yang, X.-J., Xu, L., Yang, L., & Xu, S. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117382 · Cited by 23 · see citing works

Phosphotyrosine isosteres: past, present and future

Cerulli, R. A., & Kritzer, J. A. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob01998g · Cited by 21 · see citing works

A natural product phillygenin suppresses osteosarcoma growth and metastasis by regulating the SHP-1/JAK2/STAT3 signaling

Ding, X., Lu, D., & Fan, J. (2021) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbaa007 · Cited by 21 · see citing works

Discovery and Optimization of Novel Small-molecular Inhibitors Suppressing Stat3-dependent Tumor Process

Zhang, X. (2011) · Journal of International Crisis and Risk Communication Research

Abstract 4512: A novel orally-bioavailable salicylic acid-based small molecular Stat3 inhibitor suppress growth of human breast tumor xenografts

Zhang, X., Page, B. D. G., Yue, P., Fletcher, S., Zhao, W. M., Gunning, P. T., & Turkson, J. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-4512

A Cell-permeable Stat3 SH2 Domain Mimetic Inhibits Stat3 Activation and Induces Antitumor Cell Effects in Vitro

Zhao, W. M., Jaganathan, S., & Turkson, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.154088 · Cited by 73 · see citing works

Abstract 3254: Discovery of S3I-1757, a STAT3-STAT3 dimerization disruptor that inhibits STAT3 activity, tumor survival, migration and invasion.

Zhang, X., Sun, Y., Pireddu, R., Yang, H., Urlam, M. K., Lawrence, H. R., Guida, W. C., Lawrence, N. J., & Sebti, S. M. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-3254

Abstract 1983: A cell-permeable Stat3 SH2 domain mimetic inhibitor of Stat3 activation inhibits growth of human breast tumor xenografts

Zhao, W. M., Jaganathan, S., Zhang, X., & Turkson, J. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-1983